Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 24;39(8):1701–1711. doi: 10.1093/humrep/deae112

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 1. — Study flowchart. Flow diagram of the fertility add-on study, depicting enrollment, assigned treatment according to the EuroNet-PHL-C2 protocol with corresponding cyclophosphamide equivalent dose (CED) score, and follow-up/end of study for the present study. cHL, classical Hodgkin lymphoma; COPDAC-28, cyclophosphamide, vincristine, prednisone and dacarbazine; DECOPDAC-21, doxorubicin, etoposide, cyclophosphamide, vincristine, prednisone and dacarbazine; OEPA, vincristine, etoposide, prednisone, doxorubicin; OPPA, vincristine, procarbazine, prednisone, doxorubicin; TL, treatment level; RT, radiotherapy; n, number. *a total of 5 patients assigned to TL3 (receiving OEPA induction and COPDAC-28 consolidation chemotherapy) received pelvic radiotherapy.